NVO News

Novo Nordisk's Awiqli®, the first once-weekly basal insulin for adults with type 2 diabetes, now available in the US

Next Generation Drug Conjugates Market Report (2nd Edition) | Trends, Strategies and Sales Forecast 2026-2035

Novo Nordisk A/S - share repurchase programme

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

A New Biopharma Roadmap: Zifo's SiEE Basel Event Puts Data Before AI Hype

Novo Nordisk reports adjusted operating profit of DKK 33,389 million for Q2 2026 and raises full-year outlook

Novo Nordisk raises adjusted sales and adjusted operating profit outlook for 2026

Novo Nordisk A/S - share repurchase programme

Andrew Ambrosy, Top Heart Doctor, Highlights GLP-1 and Dual GIP/GLP-1 Use for Lowering Risk of Cardiovascular Attack

Novo Nordisk provides update on the ZEUS phase 3 trial in people with ASCVD, CKD and inflammation